[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1990

Varicella-Zoster Virus Disease in Patients With Human Immunodeficiency Virus Infection

Author Affiliations

Department of Infectious Diseases Beth Israel Hospital 330 Brookline Ave/Dana 617 Boston, MA 02215

Arch Dermatol. 1990;126(8):1086-1088. doi:10.1001/archderm.1990.01670320110022
Abstract

Contact with varicella-zoster virus (VZV) is nearly universal in the United States, manifesting disease as varicella (primary infection) and herpes zoster (secondary or reactivated infection). Greater than 90% of adults in the United States show serologic evidence of previous VZV exposure. Prior to the acquired immunodeficiency syndrome (AIDS), there were an estimated three million cases of varicella and 1.5 million cases of zoster occurring annually in the United States. In 1983, VZV disease was first recognized in the context of infection with the human immunodeficiency virus (HIV). Since that time, there have been many reports on the occurrence and clinical manifestations of herpes zoster in HIV-infected patients and, more recently, the occurrence of primary varicella in such patients. In this issue of the Archives,1-3 three reports describe various aspects of VZV disease in the context of HIV infection.

Prior to AIDS, the annual incidence of herpes zoster in the general population was about

First Page Preview View Large
First page PDF preview
First page PDF preview
×